

Neurotech

21 August 2020

Neurotech Receives Promising Early Results from Cannabinoid Analysis

Highlights

- Positive results returned from the first 40 samples as part of cannabinoid genetic profiling and analysis by ACS Laboratories
- Analysis has detected a “variety” of cannabinoid profile across all 40 samples, with levels of cannabinoid CBDA up to approx. 12% with low THC; rare cannabinoids CBGA, CBG and THCA also detected
- Full results from ACS’ analysis expected in early September 2020
- Cannabinoid assessment is part of NTI’s recent option to acquire an exclusive worldwide licence to use proprietary cannabis strains from Dolce Cann Global for medicinal use in treating neurological disorders such as autism, epilepsy and ADHD
- Depending on final results, following ACS Laboratories analysis, NTI plans to commence *in-vitro* testing (using human derived cell lines) on the key priority strains
- If testing is successful, NTI will commence clinical trials with an Australian university, utilising Dolce cannabis strains and its own proprietary Mente autism neurofeedback device which analyses brain wave activity

Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce it has received promising early results from ACS Laboratories’ (“ACS”) genetic profiling and full potency analysis on the cannabis samples, as Neurotech investigates the potential of cannabinoids for medicinal use in treating neurological disorders including autism, epilepsy and ADHD.

ACS has reported that the first 40 samples have returned a “wide cannabinoid profile” with levels of cannabinoid CBDA up to approx. 12% (with less than 0.5% THC) as well as “rarer” cannabinoids such as CBGA, CBG and THCA in the samples. The 40 samples represent approximately half of those sent to ACS for analysis from Dolce Cann Global Pty Ltd (“Dolce”) as part of Neurotech’s option to acquire an exclusive worldwide licence to utilise Dolce’s proprietary strains, announced in July 2020. Samples were analysed using well-established and published High Performance Liquid Chromatography Ultraviolet (HPLC/UV) and Mass Spectrometry (MS) methods. An analytical screen was carried out on 10 major cannabinoids.

Neurotech Chairman Mark Davies said the early results from ACS’ assessment was promising for Neurotech’s plans for *in-vitro* testing on the lead cannabinoid candidates once genetic profiling is complete.

“Our midway analysis is on track. Samples to date contain significant amounts of the cannabinoid CBDA, which is shown to have promise in treating inflammation and anxiety as well as neuro-protection, and our

samples also contain an array of “rare” cannabinoids in their native form, form, such as THCA and CBGA. “These cannabinoids need further analysis to quantitate the levels as they were only recently discovered and there is not much research available on them yet.

“But at this point, considering this analysis is just the starting point of our research, these are early impressive results. We look forward to testing the lead candidates *in-vitro* if the remainder of ACS’ analysis is consistent with these early results.”

ACS Laboratories is a leader in medicinal cannabis analytical services with Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) and has National Association of Testing Authorities (NATA) accreditation. It expects to have full results from profiling and potency analysis of all 80 samples in early September.

Neurotech plans to commence *in-vitro* testing (using human derived cell lines) in September 2020, and will use results from ACS’ analysis to determine the key priority strains to target autism and other neurological disorders.

Neurotech is using samples from Australia-based Dolce, which has proprietary genetics sourced from 13 rare chemovars. This is bolstered over the past 20 years by selective breeding targeted for distinct purposes such as cultivation method, climate, yield, phytochemical content and harvested products including flower, seed, fibre or biomass.

The benefits of cannabinoid CBDA are only just beginning to be understood, but it has shown to have anxiolytic, antipsychotic and neuroprotective properties. In addition, basic and clinical investigations on the effects of CBDA have been carried out in the context of many other health conditions, including its potential use in epilepsy, substance abuse and dependence, schizophrenia, social phobia, post-traumatic stress, depression, bipolar disorder, sleep disorders, and Parkinson.

The Company looks forward to updating shareholders shortly with the profiling and potency analysis of the full set of samples.

Authority

This announcement has been authorised for release by the Board of Directors of the Company.

Further Information

Mark Davies
Chairman
md@1861capital.com.au
+61 413137887

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical

neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com

Annexure A

Sample Name	CBDV	CBDA	CBGA	CBG	CBD	THCV	THC	d8-THC	CBC	THCA
24455-1	0.05	3.68	0.25	0.05	0.27		0.06	0.05		0.17
24455-2	0.1	5.79	0.34		0.39	0.06	0.07			0.24
24455-3	0.12	6.65	0.51	0.09	0.29		0.06	0.05		0.28
24455-4	0.12	1.94	0.26		0.11	0.05	0.06			0.13
24455-5	0.08	2.55	0.39		0.14	0.07	0.17	0.06		1.19
24455-6	0.09	4.87	0.3		0.46		0.08	0.06		0.21
24455-7	0.08	5.3	0.32	0.11	0.42		0.12	0.06		0.43
24455-8	0.07	5.35	0.33	0.07	0.5	0.05	0.08	0.05	0.09	0.22
24455-9	0.06	9.46	0.49	0.13	0.41	0.08	0.14	0.09		0.36
24455-10	0.08	6.55	0.46		0.29	0.05	0.09	0.07		0.26
24455-11	0.04	5.93	0.73	0.09	0.26	0.07	0.07	0.05		0.25
24455-12	0.06	7.43	1		0.2	0.06	0.25			2.9
24455-13	0.05	5.49	0.32	0.1	0.32	0.09	0.09	0.06		0.24
24455-14	0.12	2.83	0.31		0.19	0.06	0.06	0.05		0.16
24455-15	0.05	9.82	0.59		0.17	0.06	0.07	0.07		0.39
24455-16	0.06	11.86	0.44	0.12	0.37	0.1	0.08			0.45
24455-17	0.06	2.34	0.29	0.07	0.1	0.06	0.14	0.05		1.11
24455-18	0.09	4.98	0.68	0.09	0.24	0.07	0.06	0.07		0.22
24455-19A	0.09	4.73	0.22	0.07	0.16	0.12	0.06			0.23
24455-19B	0.08	4.87	0.22	0.08	0.12	0.06	0.08	0.1		0.24
24445-20	0.05	4.29	0.28	0.09	0.37		0			0.19
24445-21	0.04	6.88	0.63	0.08	0.28		0.03	0		0.28
24445-22	0.04	2.38	0.16	0.04	0.12		0.01			0.13
24445-23	0.06	4.74	0.22		0.35		0.01	0		0.21
24445-24	0.09	3.08	0.24	0.06	0.27	0.02	0			0.16
24445-25	0.08	6.17	0.18	0.06	0.54		0.04	0	0.1	0.24
24445-26	0.07	6.09	0.43	0.09	0.17	0	0.03			0.26
24445-27	0.06	3.79	0.28		0.17		0.01	0		0.19
24445-28	0.18	4.45	0.47	0.12	0.41	0.01	0.02			0.2
24445-29	0.15	5.78	0.36	0.09	1.09		0.07	0	0.13	0.23
24445-30	0.06	6.64	0.51	0.11	0.21	0	0			0.28
24445-31	0.13	5.82	0.68		0.19	0.01	0			0.26
24445-32	0.08	3.46	0.3	0.06	0.25		0.02			0.18
24445-33	0.06	5.03	0.33	0.12	0.37	0	0.03			0.22
24445-34	0.12	8.77	0.81	0.14	0.47	0.02	0.04	0	0.1	0.35
24445-35	0.05	2.53	0.18		0.32		0.05	0.01		0.14
24445-36	0.06	6.38	0.37		0.32	0.05	0.01			0.26
24445-37	0.12	3.04	0.36	0.06	0.31		0.01			0.16
24445-38	0.05	7.33	0.57	0.12	0.38	0.03	0.02	0		0.3
24445-39A	0.03	2.28	0.14		0.12		0.01			0.14
24445-39B	0.05	2.13	0.13		0.11		0	0.01		0.14

Data is %